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Abstract
Background: There is growing evidence of subclinical inflammation in mental disorders. Objective: The aim of this study was to investigate frequency of 
symptoms of catatonia and the newly diagnosed subclinical inflammatory markers which are neutrophil/lymphocyte (NLR), platelet/lymphocyte (PLR), 
monocyte/lymphocyte (MLR) ratios in catatonia patients due to mental disorders. Methods: Patients who were admitted to psychiatry clinic with the diagnosis 
of catatonia according to DSM 5 in the last two years and equal number of control group were included in this retrospective study. Univariate analysis of 
covariance controlled for possible confounders was used to compare NLR, PLR, MLR ratios between patients and the control group. Results: A total of 34 
catatonia patients and 34 healthy controls were included in the study. Patients’ mean age was 30.88 + 13.4. NLR value was significantly higher in the patient 
group than control group. There was no significant difference between the patients and control group according to PLR, MLR values. Discussion: The presence 
of subclinical inflammation in catatonic syndrome due to mental disorders should be considered. Subclinical inflammation that was observed in numerous 
mental disorders continues in catatonia due to mental disorders. Large-scale studies are needed to determine the role of inflammation in catatonia.
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Introduction
Catatonia, first described by Karl Kahlbaum, is a neuropsychiatric 
disorder characterized by the presence of motor, behavioral, 
emotional and vegetative symptoms1. DSM-IV included the 
schizophrenia catatonic subtype. Catatonic type: a type of 
schizophrenia in which the clinical picture is dominated by at least 
two of the following: 1) motoric immobility as evidenced by catalepsy 
(including waxy flexibility) or stupor; 2) excessive motor activity (that 
is apparently purposeless and not influenced by external stimuli); 
3) extreme negativism (an apparently motiveless resistance to all 
instructions or maintenance of a rigid posture against attempts to 
be moved) or mutism; 4) peculiarities of voluntary movement as 
evidenced by posturing (voluntary assumption of inappropriate or 
bizarre postures), stereotyped movements, prominent mannerisms, 
or prominent grimacing; 5) echolalia or echopraxia. In DSM-5 
catatonia is defined by the presence of three or more of the following 
symptoms; stupor, catalepsy, waxy flexibility, mutism, negativism, 
posturing, mannerism, stereotypes, agitation, grimacing, echolalia, 
echopraxia2. The most common catatonic symptoms are staring, 
mutism, negativism, stupor, withdrawal, rigidity, posturing and 
catalepsy3,4. It can be seen as neurological disorders, endocrine, 
metabolic disorders, acute onset due to systemic infections and also 
psychiatric conditions5 and it is increasingly becoming one of the 
main psychopathological areas within the spectrum of schizophrenia 
and other psychotic disorders and mood disorders6.
It has been thought that there is central GABAergic, dopaminergic 
and glutamatergic dysfunction in physiopathology of catatonia7. 
Its pathophysiology is not clearly understood7. Medical catatonia 
is related to inflammation, neural damage, neurodevelopmental 
disorders, structural brain pathologies that affect central nervous 
system8. Researches on etiological basis of catatonia due to psychiatric 
disorders are still insufficient. Various evidence has been put forward 
regarding familial-genetic factors9.
Subclinical inflammation is defined as a low grade inflammatory 
which may continue in symptom free periods of inflamatuar 
diseases10-12. High-sensitive C-reactive protein (hs-CRP), interleukin 
6 (IL-6), IL-1 receptor antagonist are some of the subclinical 
inflammatory markers which were used in clinical studies13-15. 
Subclinical inflammation has been described in also mental disorders 
like major depressive disorder, bipolar disorder, schizophrenia and 
schizoaffective disorder which can be presented with catatonia15-17. 
Recent studies support this inflammation hypothesis in severe 
mental disorders18. In fact, the evidence of subclinical inflammation 
presence in mental disorders that do not exhibit catatonic features 
is also prominent19-21. However, the role of inflammation in mental 
disorders is not clearly understood. Also there are studies suggest that 
auto-immune diseases increase the risk of schizophrenia and bipolar 
disorders21,22. It has been reported that systemic lupus erythematous 
which is a chronic inflammatory auto-immune disease presented 
with catatonia symptoms and was improved with lupus treatment23. 
One of the determinants of chronic inflammation is the white 
blood cell count and its subtypes. Neutrophil/lymphocyte ratio 
(NLR) is a new parameter indicating the subclinical inflammation24,25. 
Recently, platelet/lymphocyte (PLR), monocyte/lymphocyte (MLR) 
ratio has been used to determine inflammation26,27.
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In this study, we aimed to explore the frequency of symptoms 
of catatonia in primary outcome and investigate whether there is an 
increase in NLR, PLR, and MLR in catatonia patients as part of mental 
disorders that have been implicated with subclinical inflammation 
as secondary outcome.
Methods
Patients diagnosed with catatonia according to the DSM-5 criteria 
and treated in the psychiatry clinic were included in this retrospective 
study between November 2016 and November 2018. The approval for 
the study was obtained from the Ethics Committee before collection 
of data. Totally 43 patients were detected in this review of inpatients 
records. Patients with severe neurological disease, diabetes mellitus 
and other endocrinopathies, patients with liver disease, malignant 
disease, mental retardation, obesity (BMI ≥ 30), pregnancy, using 
anti-inflammatory drugs (NSAIDs, corticosteroids) and alcohol/
substance use disorder or addiction history were excluded from the 
study. Rest of the patients (34) were included the study. Symptoms 
of the patients according to DSM 5 criteria were examined. Magnetic 
resonance imaging without contrast had been performed in all 
patients and no organic brain damage had been observed. Patients’ 
hemoglobin values had been within normal range. Preliminary 
evaluation of all patients had been completed and patients had not 
had any active infections. Patients’ thyroid stimulant hormone values 
had been within normal range. No substance had been detected 
in the urine. The control group was chosen as the last 34 healthy 
individuals without any disabilities who applied to the health board 
in the last 6 months. 
Sociodemographic and clinical variables as age, gender, 
education, smoking status, weight and length had been recorded. 
Weight/length2 (kg/m2) formula was used to calculate BMI.
NLR, PLR, MLR which are subclinical inflammatory markers 
were compared between 34 patients and 34 control groups. 
Descriptive statistics were used for the demographic characteristics 
of 34 patients with catatonia. χ2 test was used to compare categorical 
variables. t-test was used for comparison of normally distributed 
variables between the two groups. Mann-Whitney U test was used 
for comparison of abnormal distributed variables. Finally, the 
effects of factors such as age, sex, smoking and BMI on NLR, PLR, 
MLR levels of patients were analyzed using univariate analysis of 
covariance (ANCOVA). SPSS 22.0 (IBM Corporation, Armonk, 
New York, United States) software was used in the analysis of 
variables.
Results
A total of 68 cases (34 catatonia and 34 healthy controls) were 
included in our study. Eighteen patients (53%) were female, 16 
were male (47%). Mean age was 30.88 + 13.4; mean education years 
were 6.08 + 3.2. Seven of the catatonia patients had no psychiatric 
diagnosis in the past. Of these 7 patients who were admitted for 
catatonia for the first time, 3 were diagnosed with bipolar manic 
episode and 4 with major depression at the end of the treatment in 
psychiatry clinic. Of the 27 patients who had psychiatric follow-up in 
the past, 5 had schizophrenia, 14 had bipolar disorder (9 had manic 
episodes before catatonia, 5 had depressive episodes) and 8 had major 
depression (4 with psychotic features). There were no significant 
differences between the groups in terms of age, sex, smoking and 
marital status (Table 1).
The most common symptoms in patients were mutism 70.5% 
and negativism 64.7%. The symptoms and frequencies according to 
DSM 5 are shown in Table 2.
NLR ratio was significantly higher in patients with catatonia 
compared to controls (p = 0.004). No difference was found between 
the patient and the control group in terms of MLR, PLR (Table 3).
Covariance analysis revealed that NLR levels were significantly 
higher in patients compared to control group (Table 4).
Table 2. Frequency of catatonia symptoms according to DSM 5 criteria
Catatonia symptoms Symptom frequency
Mutism 24 (70.5%)
Negativism 22 (64.7%)










Table 3. Comparison of NLR, PLR, MLR of patients and control group
Mean ± standard deviation P
Catatonia Control
NLR 2.81 ± 1.5 1.95 ± 0.70 0.004*
MLR 0.33 ± 0.1 0.27 ± 0.1 0.080
PLR 134.0 ± 47.2 147.1 ± 52.6 0.287
*p<0.05
Table 4. Results of NLR, PLR, MLR levels between patients and control 
group with ANCOVA
Mean ± standard error P
Catatonia Control
NLR 2.85 ± 0.20 2.09 ± 0.21 0.010*
MLR 0.33 ± 0.02 0.29 ± 0.02 0.298
PLR 133.8 ± 8.6 154.7 ± 8.9 0.100
*p<0.05
Table 1. Sociodemogrophic data
Case control P
Catatonia Control
Sex Male 16 (47%) 13 (38.2%) 0.469
Female 18 (53%) 21(61.8%)
Age 30.88 ± 13.4 36,4 ± 12,2 0.084
Education (year) 6.08 ± 3.2 7,58 ± 3,7 0.086
Body mass index 23.5 ± 7.5 22.9 ± 1.26 0.054
Smoke Yes 14 11 0.458
No 20 23
Marital Status Married 20 26 0.097
Single 14 8
Discussion
In this study, we investigated NLR, PLR, and MLR in catatonia 
patients as part of mental disorders that have been implicated with 
subclinical inflammation. The results of our study put forth that there 
is a subclinical inflammation (higher NLR) in catatonia patients 
due to mental disorders. Additionally, frequency of clinical features 
related with catatonia will be discussed.
The first finding of our study is the frequency of mood disorders in 
catatonia patients. Catatonia is associated with many pathophysiological 
processes and is most commonly associated with mood disorders28. In 
our study, 29/34 (85%) of the patients were followed up with mood 
disorder and 17/34 (50%) with bipolar disorder. 
Excitation (72.7%), immobility/stupor (21.4%) and mutism 
(15.6%) were reported as the most common symptoms in catatonia 
due to medical conditions28. We found that mutism (70.5%) and 
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As a result, the presence of a subclinical inflammation in the 
catatonic syndrome due to mental disorder should be considered in 
addition to medical and neurological conditions. NLR as a subclinical 
inflammatory marker is higher in catatonia. Subclinical inflammation 
that was observed in numerous mental disorders continues in 
catatonia due to mental disorders. NLR may be a more reliable 
marker for subclinical inflammation in severe mental disorders. This 
study will guide the future studies in the evaluation of the etiology 
of catatonia and evaluation of treatment options.
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